What You'll Learn
Table of Contents
What GLP-1 Is (The Hormone)
GLP-1, short for glucagon-like peptide-1, is a hormone your own gut releases after you eat. It does three things worth knowing: it tells your pancreas to release insulin, it slows down how fast food leaves your stomach, and it signals fullness to your brain. It's part of a broader hormone family called incretins, released in response to food already in the gut.
The catch is that natural GLP-1 breaks down within minutes. Synthetic versions were engineered specifically to resist that breakdown, so the same effects last for hours — or, in the case of once-weekly formulations, days.
What GLP-1 Medications Are (The Drug Class)
GLP-1 medications, formally called GLP-1 receptor agonists, are drugs engineered to bind the same receptor as the natural hormone and activate it more strongly and for much longer. That amplified, sustained signal is what produces the clinical effects seen in trials: improved blood sugar control and, at higher doses developed specifically for this purpose, substantial appetite reduction and weight loss.
Bottom line: These aren't a new mechanism invented for weight loss — they're an amplification of a hormone your body already makes and uses every time you eat.
How They're Different From Insulin
GLP-1 medications are frequently confused with insulin, but they work upstream of it. Insulin directly lowers blood sugar by moving glucose into cells. GLP-1 medications instead prompt the pancreas to release its own insulin only when blood sugar is elevated, which is part of why they carry a lower standalone hypoglycemia risk than insulin therapy — that risk rises mainly when GLP-1 drugs are combined with insulin or sulfonylureas.
HealthRX — physician-supervised GLP-1 care
This page explains what the drugs are and how they work. It cannot tell you whether you qualify for one — that needs a licensed provider reviewing your history, your BMI and what else you take. HealthRX runs that intake online.
See what the intake involves →Disclosure: we earn a commission if you start a plan through this link, at no extra cost to you. It does not change what this page says. HealthRX dispenses compounded semaglutide and tirzepatide, which are pharmacy-prepared formulations, not the FDA-approved branded products. Nothing on this page is medical advice — that is what the provider review is for.
The Major Drugs in This Class
| Active ingredient | Brand names | FDA-approved for | Dosing |
|---|---|---|---|
| Semaglutide | Ozempic, Wegovy | Ozempic: type 2 diabetes. Wegovy: chronic weight management. | Once weekly, injectable |
| Tirzepatide | Mounjaro, Zepbound | Mounjaro: type 2 diabetes. Zepbound: chronic weight management. | Once weekly, injectable |
| Liraglutide | Victoza, Saxenda | Victoza: type 2 diabetes. Saxenda: chronic weight management. | Once daily, injectable |
| Dulaglutide | Trulicity | Type 2 diabetes | Once weekly, injectable |
Tirzepatide is structurally different from the other three: it's a dual GIP/GLP-1 receptor agonist, meaning it activates two incretin hormone receptors instead of one. Trial data associates this dual mechanism with larger average weight loss than single-receptor semaglutide — see the numbers below.
What the Evidence Shows They Do
Three large, pivotal randomized controlled trials anchor almost everything reliably known about this drug class. This is deliberately the shortest, most citation-dense section of this guide — these are the numbers everything else in this GLP-1 series builds on.
The pivotal trial for semaglutide 2.4mg in adults with overweight or obesity, without diabetes. 86% of participants on semaglutide lost at least 5% of body weight, versus a much smaller placebo response.
DOI: 10.1056/NEJMoa2032183 ↗The pivotal trial for tirzepatide across its 5mg, 10mg, and 15mg doses in adults with obesity or overweight, showing a dose-dependent effect larger than semaglutide's single-receptor mechanism.
PMID: 35658024 ↗In adults with pre-existing cardiovascular disease and overweight/obesity but without diabetes, semaglutide reduced cardiovascular death risk compared with placebo — the first trial to establish a hard cardiovascular-outcome benefit for this class independent of a diabetes diagnosis.
PMID: 37952131 ↗Beyond weight and cardiovascular outcomes, this class was originally developed for, and remains approved for, blood-sugar control in type 2 diabetes — that was its first and best-established use, well before the weight-management indication existed.
What They Don't Do
- They aren't a cure for obesity. Current clinical guidelines treat obesity as a chronic, relapsing condition — these drugs manage it, similar to how blood-pressure medication manages hypertension, not resolve it permanently.
- They don't preserve muscle automatically. Body-composition trial data shows some of the weight lost is lean mass, not just fat — see our full guide on GLP-1 and muscle loss for what actually prevents this.
- They don't work identically for everyone. Trial results are averages; the range of individual responses is wide.
- They don't remove the need for nutrition or activity. Every pivotal trial paired the drug with a lifestyle/nutrition intervention arm, not the drug alone.
Important: This article is educational, not medical advice, and does not recommend or provide dosing guidance for any prescription medication. GLP-1 medications require a prescription and ongoing medical supervision.
Who They're Approved For
FDA-approved indications vary by specific drug and brand, but generally fall into two categories: type 2 diabetes management, or chronic weight management in adults with a qualifying BMI (commonly BMI ≥30, or ≥27 with a weight-related condition such as hypertension or type 2 diabetes). Eligibility is a clinical decision made with a prescribing physician based on an individual's full health picture — this guide describes the general approval categories, not a self-assessment tool.
